Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CARTS study in distal rectal cancer
NL-OMON35364Phase 2Recruiting
- Sponsor
- Dutch Colorectal Cancer Group
- Start
- Nov 2010
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of capecitabine in rectal cancer and rectal adenocarcinoma, sponsored by Dutch Colorectal Cancer Group. Primary endpoint: Primary response endpoint. Started Nov 2010; status: recruiting.
02
Drugs
capecitabine
03
Conditions
rectal cancerrectal adenocarcinoma
Beyond the preview
Go deeper on NL-OMON35364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON35364.